Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181571 | 0.83 | L3MBTL1 (0.52) | L3MBTL1PRMT5WDR77PIK3CDPIP5K1C | |
| SCHEMBL174122 | 0.83 | — | — | |
| SCHEMBL18083219 | 0.82 | L3MBTL1 (0.50) | L3MBTL1PRMT5WDR77PIK3CDPIP5K1C | |
| SCHEMBL12311437 | 0.82 | L3MBTL1 (0.55) | L3MBTL1GABRA1GABRR1GABRA3GABRA2 | |
| SCHEMBL15721466 | 0.80 | GABRA1 (0.53) | L3MBTL1GABRA1GABRR1GABRA3GABRA2 | |
| SCHEMBL4752963 | 0.80 | L3MBTL1 (0.49) | L3MBTL1PIK3CDPIP5K1CPIK3CAPIK3CB | |
| SCHEMBL7992278 | 0.80 | L3MBTL1 (0.49) | L3MBTL1PRMT5WDR77PIK3CDPIP5K1C | |
| SCHEMBL24570289 | 0.79 | GABRA1 (0.44) | GABRA1GABRR1GABRA3GABRA2GABRB2 | |
| Hydrochloric Acid SCHEMBL26606617 | 0.78 | GABRA1 (0.43) | GABRA1GABRR1GABRA3GABRA2GABRB2 | |
| SCHEMBL10864107 | 0.78 | DRD4 (0.44) | L3MBTL1PRMT5WDR77PIK3CDPIP5K1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | L3MBTL1 3914/4885GABRA1 673/4885GABRR1 2055/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | L3MBTL1 4171/4885GABRA1 3412/4885GABRR1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.